What it is
KPV is a tripeptide: three amino acids — lysine, proline, valine. That is about as short as a peptide gets.
Those three correspond to the final three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body already produces.
Why a fragment and not the hormone
Alpha-MSH does two quite different jobs. It drives pigmentation, and it damps inflammation.
For an anti-inflammatory purpose, the pigmentation is an unwanted extra. The interest in KPV rests on published findings that this short fragment appears to retain the anti-inflammatory activity without driving pigment production.
Separating one effect of a molecule from another by using only part of it is a legitimate and well-established strategy in drug design. It is the same logic behind TB-500 being a fragment rather than the whole of thymosin beta-4 — and, as there, the fragment and the parent are not interchangeable.
What has been studied
Inflammation, and gut inflammation especially. Models of inflammatory bowel disease are among the most studied applications, with skin a secondary interest.
That work is in cells and animals. No substantial human trial evidence was located.
A connection not to draw
KPV and melanotan II both relate to the melanocortin system, and this occasionally gets used to link them.
It should not be. Melanotan II is a receptor agonist built to drive pigmentation, and it carries a substantial case-report literature of serious harms. KPV is a short fragment studied for the opposite reason — anti-inflammatory activity without pigmentation.
The melanotan II safety literature is not evidence about KPV, and it is not reassurance about it either. Neither inference holds.
Where the evidence stops
The rationale is coherent, the preclinical work is real, and the target — inflammation without the side effects of existing anti-inflammatories — is a serious one.
What has not happened is the step into people. That is the honest shape of this entry: a good idea with a genuine research basis, and no human trial evidence to point at.
The other gut-directed peptide in this library took the opposite path through development — larazotide is oral, acts on the tight junctions of the intestinal lining, and has a terminated phase 3 behind it rather than an animal literature.
Where it stands
Approved as a medicine: nowhere.
Sold as: a research chemical, injectable and increasingly in topical and oral formats.
Related entries in this library: the immune peptide thymosin alpha-1 is the one with a real trial base — 64 randomized controlled trials — and it shows what this area looks like when the questions have actually been asked.
Last checked
2026-09-07.